Literature DB >> 26310693

Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes.

Caroline Gaudy1, Céline Clévy2, Sandrine Monestier2, Noémie Dubois3, Yanis Préau3, Stéphanie Mallet2, Marie-Aleth Richard1, Jean-Jacques Grob1, René Valéro4, Sophie Béliard5.   

Abstract

Entities:  

Year:  2015        PMID： 26310693     DOI： 10.2337/dc15-1331

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  50 in total

Review 1.  Pembrolizumab (Keytruda).

Authors:  Gerry Kwok; Thomas C C Yau; Joanne W Chiu; Eric Tse; Yok-Lam Kwong
Journal:  Hum Vaccin Immunother       Date:  2016-07-11       Impact factor: 3.452

Review 2.  Checkpoint Inhibitors in Breast Cancer - Current Status and Future Directions.

Authors:  Joachim Bischoff
Journal:  Breast Care (Basel)       Date:  2018-02-20       Impact factor: 2.860

Review 3.  Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies.

Authors:  David J Byun; Jedd D Wolchok; Lynne M Rosenberg; Monica Girotra
Journal:  Nat Rev Endocrinol       Date:  2017-01-20       Impact factor: 43.330

Review 4.  Checkpoint Inhibitors.

Authors:  Lucie Heinzerling; Enrico N de Toni; Georg Schett; Gheorghe Hundorfean; Lisa Zimmer
Journal:  Dtsch Arztebl Int       Date:  2019-02-22       Impact factor: 5.594

Review 5.  Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management.

Authors:  Jonathan W Goldman; Melody A Mendenhall; Sarah R Rettinger
Journal:  Oncologist       Date:  2016-07-29

Review 6.  Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update.

Authors:  Hiroki Nagai; Manabu Muto
Journal:  Int J Clin Oncol       Date:  2018-03-07       Impact factor: 3.402

7.  Diabetes mellitus secondary to treatment with immune checkpoint inhibitors.

Authors:  V Venetsanaki; A Boutis; A Chrisoulidou; P Papakotoulas
Journal:  Curr Oncol       Date:  2019-02-01       Impact factor: 3.677

8.  Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma.

Authors:  Jasna Aleksova; Peter K H Lau; Georgia Soldatos; Grant McArthur
Journal:  BMJ Case Rep       Date:  2016-11-23

9.  Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma.

Authors:  Wataru Munakata; Ken Ohashi; Nobuhiko Yamauchi; Kensei Tobinai
Journal:  Int J Hematol       Date:  2016-10-01       Impact factor: 2.490

10.  New onset diabetes after nivolumab treatment.

Authors:  Ricardo Capitao; Carlos Bello; Ricardo Fonseca; Catarina Saraiva
Journal:  BMJ Case Rep       Date:  2018-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.